AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01917318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone
Description: Subjects will receive oral iloperidone for 8 weeks. The first 2 weeks of treatment is called titration period and during this time the dose of iloperidone will be increased periodically from 1mg to a maximum of 8mg depending on response and tolerability.~During the remaining 6 weeks of treatment, called stable dose period, the subjects will receive a stable dose of iloperidone(defined during titration period)
Study NCT01020175 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bone marrow transplantation
Description: Patients received bone marrow transplantation
Study NCT01917318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: During 8 weeks subjects will receive oral placebo
Study NCT03185338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Physical Education lessons
Description: Specific lessons designed for increasing moderate to vigorous physical activity in Physical Education will be applied
Study NCT03185338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active school recess
Description: Teachers will design games and activities and will encourage children for being active
Study NCT03185338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep health promotion
Description: This intervention will aim to raise the awareness of the importance of having a good quality sleep at night and to teach healthy sleep behaviours that will contribute to improving sleep hygiene
Study NCT03185338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School global intervention
Description: A simultaneous implementation of all four interventions (see the others arms) will be examined in one of the intervention schools.
Study NCT03087578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupncture
Description: Patients will receive electroacupuncture treatment for 30 minutes per weekly session for 6 weeks.
Study NCT02791243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride 0.25%
Description: Cutaneous solution of finasteride 0.25%
Study NCT02791243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Finasteride 0.25%
Description: vehicle cutaneous solution of P-3074
Study NCT02791243 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Negative Control
Description: 0.9% aqueous NaCl
Study NCT01650402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-hypertensive therapy to SBP 130 mm Hg
Description: Anti-hypertensive therapy to achieve 24 hour systolic blood pressure less than or equal to 130 mm Hg
Study NCT01650402 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anti-hypertensive therapy to SBP 145 mm Hg
Description: Anti-hypertensive therapy to achieve 24 hour systolic blood pressure less than or equal to 145 mm Hg
Study NCT02002325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tissue-type plasminogen activator (alteplase)
Description: Intravenous tissue-type plasminogen activator (alteplase) 0.6mg/kg body-weight up to a maximum of 60 mg, 10% as bolus, 90% over 1 hour as infusion (plus other standard treatment if needed)
Study NCT02002325 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Standard treatment for acute stroke without intravenous alteplase.
Study NCT00982384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Disease management
Description: Disease management by COPD nurses, including active follow-up and coordination of care in addition to best care according to clinical guidelines for COPD patients
Study NCT00982384 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best care
Description: Comprehensive care for COPD patients recommended in clinical guidelines
Study NCT04259593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Study NCT03087578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron 50 MG [Myrbetriq]
Description: Patients will receive 50 mg of mirabegron daily for 6 weeks.
Study NCT04698213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib Oral Tablet
Description: Axitinib is an orally bioavailable tyrosine kinase inhibitor currently approved in EU for treatment of patients affected by metastatic renal cell carcinoma (mRCC) progressed after another anti VEGFR-tyrosine kinase inhibitor (TKI).~Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect.
Study NCT04698213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity.
Study NCT00991380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEALD
Description: A six month, two phase pedometer-based walking program. For weeks one and two of phase I, participants will attend a group-based 60 minute education/supervised walking session. They will be asked to set a daily step goal and to attempt to achieve this on a daily basis over three months. Their steps will be recorded in a step log. For weeks one and two of phase II, participants will learn how to increase the speed of a portion of their daily steps and will learn the concept of low glycemic index and how to set dietary goals related to this concept. They will attend two sixty minute group-based education/supervised walking sessions.
Study NCT00991380 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Control
Study NCT00463658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Falls Prevention
Description: Subjects in the interdisciplinary group will receive home care services from a team of professional service providers (CCAC Case Manager, Public Health Nurse (Registered Nurse), Occupational Therapist, Physiotherapist, Nutritionist) with experience and training in falls prevention. The team will provide a comprehensive, coordinated and evidence based approach to falls prevention through weekly case conferencing, a written interdisciplinary care plan, and joint client visits.
Study NCT00401076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA-001
Description: 0.25 g of SA-001 pellets/capsule, 12 capsules/day for 52 weeks
Study NCT00863161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3355
Description: capsule, oral, single dose
Study NCT03114267 — intervention group
Intervention type: OTHER
Intervention: Comparison of the prevalences of the parvovirus genome
Description: Comparison of the prevalences of the parvovirus genome between cases and controls and then of other viruses according to the results of parvoviruses and data from the literature
Study NCT01220661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefotetan
Description: preoperative one dose prophylactic antibiotic (2g iv, within 1 hour before skin incision)
Study NCT00081250 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine monohydrate
Description: Given orally
Study NCT00081250 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT03411369 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine, D-Ribose, B1 Vitamin, and B6 vitamin
Description: The treatment will consist of taking 2 sachets / day for the first two weeks, and then continuing with 1 sachet/day for the next month.
Study NCT03411369 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Water-soluble powder in sachets of 4 grams containing inert product consisting of starch powder.
Study NCT00788853 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: No treatment is given
Study NCT02146443 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretched arm test
Description: Measurement of static arm strength. Test subject is asked to hold a 2.5 kg weight in their dominant arm fully extended at 90-degree flexion and 15-degree abduction as long as possible without moving.
Study NCT04381143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100 mg Oral Tablet
Description: Aspirin 100 mg tablet daily
Study NCT04381143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo 1 pill daily
Study NCT01020175 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Peripheral blood stem cell transplantation
Description: Patients received filgrastim-mobilized peripheral blood stem cell transplantation
Study NCT02146443 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stress
Description: During completion of the star shaped manual dexterity test, the test subject is asked to identify cards from a regular deck of playing card by naming the suit and rank of the card. They will be asked to identify one random card during each of the 10 rounds in the completion of the test
Study NCT01466153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab was administered by IV infusion as a dose of 375 mg/m\^2 on Day 2 of Cycle 1 and then at 500 mg/m\^2 on Day 1 of up to 5 subsequent 28-day cycles
Study NCT01466153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine was administered by IV infusion as a dose of 70 mg/m\^2 on Day 1 and Day 2 of each 5 subsequent 28-day cycle.
Study NCT02051894 — intervention group
Intervention type: DRUG
Intervention: Dobutamine
Description: Infants will receive treatment according to the preference of the responsible physician. As is common practice, dobutamine, dopamine and/or other treatments (including other cardiovascular drugs and/or volume replacement therapy with normal saline) will be administered.~If dobutamine is used we will take a maximum of two blood samples from the baby for pharmacokinetic analysis.
Study NCT00605410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ipratropium bromide
Description: 2 puffs (40 micrograms) 2 puffs (0micrograms)
Study NCT00605410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matched placebo
Study NCT01822691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB024360
Description: INCB024360 is an inhibitor of the enzyme indoleamine 2,3-dioxygenase (IDO) that is proposed for development for the treatment of malignant diseases. Participants were to receive the study drug in 28 day (4 week) cycles of treatment.
Study NCT01413048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol 25mg
Description: Tablet, q.d.
Study NCT01413048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGSCT101 12.5mg
Description: Tablet, q.d.
Study NCT03177980 — intervention group
Intervention type: DRUG
Intervention: Fentanyl
Description: The dosing and administration of fentanyl will serve as the first drug intervention in infants in need of analgesia according to an algorithm based on pain scoring results.
Study NCT01466153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Bendamustine was administered by IV infusion as a dose of 70 mg/m\^2 on Day 1 and Day 2 of each 5 subsequent 28-day cycle.
Study NCT01466153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551
Description: MEDI-551 was administered at 2 mg/kg or 4 mg/kg by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycles.
Study NCT02146443 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Star shaped manual dexterity test
Description: On a piece of wood, a piece of metal (dimensions 22 cm x 22 cm) is mounted. In the center of the metal plate, is a star shaped track. The star has 6 points and the track is 9 mm wide. It measures 15,3 cm from the tips of opposing arms of the star. With a surgical scissor in his dominant hand, the test subject is instructed to follow the star shaped track ten times, five times clockwise and five times counter clockwise. Contact with the border of the track is counted as an error. A computer software program automatically registers completion time and number of errors. The test is conducted in an undisturbed environment.
Study NCT02099175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m2 or 33 mg/m2 or 100 mg/m2 - Concentrate for solution for infusion.
Study NCT03177980 — intervention group
Intervention type: DRUG
Intervention: Fentanyl and clonidine
Description: In infants in need of further analgesia clonidine will be administered as an add on drug according to an algorithm based on pain scoring results.
Study NCT01605591 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the DLT bending to the right
Description: bending the bronchial lumen of DLT 60\~90 degrees in the same side with the tracheal lumen
Study NCT01605591 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the DLT bending to the left
Description: bending the bronchial lumen of DLT 60\~90 degree opposed to the tracheal lumen
Study NCT00733382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethazone
Description: injection form, 8 miligram, injected once
Study NCT00733382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethazone
Description: injection form, 8 miligram, injected once
Study NCT00745368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400 mg tablets twice daily during duration of trial
Study NCT04330976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and physical activity intervention
Description: Messages sent on nutrition and physical activity in pregnancy
Study NCT04330976 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Messages sent on general health during pregnancy
Study NCT00361712 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preemptive epidural analgesia
Description: Parturients will receive early epidural analgesia before onset of painful contractions as oppose to standard of care in which parturients receive epidural analgesia with onset of painful contractions.
Study NCT00361712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Epidural analgesia with parturients with cervical dilatation and painful labor (VAS >5)
Study NCT01919645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Training ( Strength + Aerobics)
Description: Strength training performed using workout devices and aerobic training performed using stationary bicycle.
Study NCT01919645 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Combined Training ( Strength + Aerobics)
Description: Strength training performed using workout devices and aerobic training performed using stationary bicycle.
Study NCT04052919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac dysfunction in adolescents with type 1 diabetes
Description: to identify specific parameters related to glucoregulation which correlate with cardiac function and structure in adolescent with T1DM.~In T1DM, exercise training to have beneficial effects on HbA1c levels, cardiovascular risk profile.~To evaluate the association between cardiac function/structure and cardiopulmonary exercise capacity in adolescent T1DM patients (in the perspective of their physical activity behavior). This study thus may provide greater insights in the etiology and consequences of a disturbed cardiac function/structure in adolescents with T1DM.
Study NCT02885142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local excision for early rectal cancer
Study NCT02885142 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local excision for early rectal cancer
Study NCT02135965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol 4mg and Caffeine 100mg
Description: Albuterol 4mg and Caffeine 100mg on metabolic rate
Study NCT02891525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 50g glucose
Study NCT02891525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 25g fructose
Study NCT02891525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 220mg acesulfame-K
Study NCT02135965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol 4mg and Caffeine 200mg
Description: Albuterol 4mg and Caffeine 200mg on metabolic rate
Study NCT01507090 — intervention group
Intervention type: DEVICE
Intervention: Mercy TAPE
Description: 2D Mercy TAPE and 3D Mercy TAPE
Study NCT03654664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine
Description: Inactivated hepatitis A virus antigen 250 U (Name of viral strain: TZ84)
Study NCT03654664 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix Inj
Description: 720 ELISA/0.5 mL Junior (Inactivated hepatitis A virus antigen 160 U (Name of viral strain: HM175 Inj)
Study NCT01739634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CASAD
Description: CASAD is provided in 500mg capsules.
Study NCT02610920 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Iron-tracer guided axillary ultrasound and biopsy
Description: After ultrasound identifying sentinel lymph nodes, no more than two nodes will be core-needle biopsied and sent to pathology department for analysis of cancer involvement. The biopsied node(s) will be marked for later identification for the surgeons during the regularly scheduled intraoperative sentinel lymph node biopsy (standard of care).
Study NCT02610920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron tracer
Description: All participants will receive a 30mg injection of subcutaneous iron sucrose into the breast followed by an axillary ultrasound looking for lymph nodes with enhanced reflexivity.
Study NCT03505814 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula Oxygen therapy (OPTIFLOW®)
Description: High flow and humidified oxygen support for new borns and young infants for post-extubation care
Study NCT03505814 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional oxygen therapy
Description: conventional oxygen support for new born and young infants in post-extubation care
Study NCT01387425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: varenicline at a dose of 1 mg twice a day for 12 week
Study NCT01387425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablet is made of lactose
Description: placebo at a dose of 1 mg twice for 12 week
Study NCT01885702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccination
Description: DC vaccination
Study NCT04686513 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: observational study
Study NCT00604227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxic Exposure
Description: ascent to 4559 m within 24 h without prior acclimatization
Study NCT01583257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workout based on active video gaming
Description: A personalized workout regimen will be provided using the Microsoft Kinect Active Gaming Console with EA Sports Active 2 program
Study NCT01164306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LifeSkills Training
Description: LifeSkills Training (Botvin's) is an evidenced based substance abuse prevention program for elementary school students to learn skills to resist tobacco, alcohol, drug abuse, and violence.~Parent LifeSkills will also be utilized. Parents are provided a parent manual and DVD to use at home with their child to reinforce what they are taught in school-based LifeSkills sessions.
Study NCT01164306 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Lifestyle Behavior Choices
Description: The healthy lifestyle behavior choices curriculum augments the state health curriculum in the assigned study schools.~Parents will also be given health related information by mail to parallel the information students receive in school health classes.
Study NCT01164306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NRT and Motivational Interviewing (MI)
Description: For parent/guardian smokers who want to quit, NRT is offered in conjunction with MI.
Study NCT02545647 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BRYGB
Description: 65 patients undergo a banded RYGB
Study NCT01829919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brisdelle (paroxetine mesylate)
Description: All subjects will receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.